Spread | 0.085 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | -0.02529% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ £5,000.00 Short position overnight fee ~ £4,000.00 | 0.003373% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | GBP | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 2.145 |
Open | 2.145 |
1-Year Change | -52.4% |
Day's Range | 2.13 - 2.305 |
Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.
10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).